Edition:
United Kingdom

Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

19.62USD
16 Aug 2019
Change (% chg)

$1.04 (+5.60%)
Prev Close
$18.58
Open
$18.64
Day's High
$19.68
Day's Low
$18.33
Volume
242,116
Avg. Vol
133,452
52-wk High
$27.00
52-wk Low
$10.30

Latest Key Developments (Source: Significant Developments)

Omeros Q2 Loss Per Share $0.29
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Omeros Corp ::ORATION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.29.Q2 EARNINGS PER SHARE ESTIMATE $-0.44 -- REFINITIV IBES DATA.OMIDRIA REVENUES FOR 2Q 2019 WERE A RECORD HIGH AT $26.8 MILLION VERSUS $21.8 MILLION IN 1Q 2019.INVENTORY ON HAND AT WHOLESALERS AT JUNE 30, 2019 REMAINED CONSISTENT WITH HISTORICAL NORMS.  Full Article

Omeros And Lonza Enter Long-Term Manufacturing Agreement For Commercial Supply Of Narsoplimab
Wednesday, 31 Jul 2019 

July 31 (Reuters) - Omeros Corp ::OMEROS AND LONZA ENTER LONG-TERM MANUFACTURING AGREEMENT FOR COMMERCIAL SUPPLY OF NARSOPLIMAB.OMEROS CORP - OMEROS AND LONZA HAVE SUCCESSFULLY PARTNERED UNDER A MULTI-YEAR MANUFACTURING AGREEMENT FOR CLINICAL SUPPLY OF NARSOPLIMAB.OMEROS CORP - NEW MULTI-YEAR AGREEMENT SECURES A SOURCE OF COMMERCIAL QUANTITIES OF NARSOPLIMAB FOR USE FOLLOWING ANTICIPATED REGULATORY APPROVALS.OMEROS CORP - LONG-TERM MANUFACTURING AGREEMENT FOR COMMERCIAL PRODUCTION OF NARSOPLIMAB.  Full Article

Omeros Reports Q4 Loss Per Share Of $0.48
Friday, 1 Mar 2019 

March 1 (Reuters) - Omeros Corp ::ORATION REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.48.Q4 EARNINGS PER SHARE ESTIMATE $-0.81 -- REFINITIV IBES DATA.Q4 REVENUE $22 MILLION.Q4 REVENUE ESTIMATE $16.7 MILLION -- REFINITIV IBES DATA.AT DECEMBER 31, 2018, COMPANY HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AVAILABLE FOR OPERATIONS OF $60.5 MILLION.  Full Article

Omeros Corp Streamlines Path To BLA For OMS721 Following Meeting With FDA
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Omeros Corp ::OMEROS CORPORATION STREAMLINES PATH TO BIOLOGICS LICENSE APPLICATION FOR OMS721 IN HSCT-TMA FOLLOWING MEETING WITH FDA.OMEROS CORP - HAS STREAMLINED REQUIRED WORK AND FURTHER ADVANCED ITS PREPARATIONS FOR ITS BIOLOGICS LICENSE APPLICATION FOR OMS721.OMEROS CORP - PATIENT DATA FROM EXISTING SINGLE-ARM STUDY WILL FORM BASIS FOR BLA; NO HISTORICAL CONTROL REQUIRED.OMEROS - PLANS TO MEET EUROPEAN REGULATORS, EXPECTS TO HARMONIZE MARKETING AUTHORIZATION APPLICATION FOR OMS721 IN HSCT-TMA IN EUROPE WITH U.S. BLA.OMEROS CORP - ENROLLING OMS721 PHASE 3 CLINICAL TRIALS FOR IMMUNOGLOBULIN A NEPHROPATHY & ATYPICAL HEMOLYTIC UREMIC SYNDROME.  Full Article

Omeros Corp Reports Preliminary Total And Omidria Q4 Revenues Of About $22 Mln
Monday, 14 Jan 2019 

Jan 14 (Reuters) - Omeros Corp ::ORATION ANNOUNCES RECORD HIGH QUARTERLY REVENUE RESULTS FOR THE FOURTH QUARTER 2018.PRELIMINARY TOTAL AND OMIDRIA REVENUES FOR Q4 OF 2018 ARE EXPECTED TO BE A RECORD HIGH AT APPROXIMATELY $22.0 MILLION.DOES NOT CURRENTLY INTEND IN FUTURE TO MAKE PUBLIC PRELIMINARY SALES REVENUES ON A ROUTINE BASIS.Q4 PRELIMINARY ANNUALIZED RUN RATE OF WEEKLY NET SALES IN DECEMBER WAS ABOUT $100 MILLION.Q4 REVENUE VIEW $13.9 MILLION -- REFINITIV IBES DATA.  Full Article

Omeros Corp Announces Clinical Strategy To Accelerate Pediatric Development Of OMS721
Thursday, 6 Dec 2018 

Dec 6 (Reuters) - Omeros Corp ::OMEROS ANNOUNCES CLINICAL STRATEGY TO ACCELERATE PEDIATRIC DEVELOPMENT OF OMS721 FOR THE TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA).OMEROS CORP - EMA CONFIRMED OMS721 ELIGIBILITY FOR EUROPEAN CENTRALIZED MARKETING AUTHORIZATION APPLICATION REVIEW.OMEROS - SUBMITTED PIP FOR USE OF OMS721 FOR TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HSCT-TMA) TO EMA.  Full Article

Sandoz Amends ANDA To Not Seek Approval For Generic Version Of Omidria
Thursday, 26 Jul 2018 

July 26 (Reuters) - Omeros Corp ::SANDOZ AMENDS ANDA TO NOT SEEK APPROVAL FOR GENERIC VERSION OF OMIDRIA UNTIL PATENTS FOR OMEROS’ DRUG EXPIRE.OMEROS CORP - WITH VOLUNTARY DISMISSAL OF INFRINGEMENT SUIT AGAINST SANDOZ, OMEROS WRAPS UP ALL PENDING ANDA LITIGATION.  Full Article

Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing
Thursday, 24 May 2018 

May 24 (Reuters) - Lupin Ltd ::OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING.OMEROS - AGREEMENT RESOLVES CO'S PATENT LITIGATION AGAINST LUPIN.OMEROS CORP - LUPIN ACKNOWLEDGED & CONFIRMED VALIDITY OF EACH OF PATENTS LISTED IN ORANGE BOOK FOR OMIDRIA.OMEROS CORP - PARTIES EXECUTED CONSENT JUDGMENT THAT WAS FILED WITH COURT FOR DISTRICT ON MAY 23, 2018.OMEROS - LUPIN GRANTED LICENSE TO MAKE, SELL GENERIC VERSION OF OMIDRIA BETWEEN PERMITTED LAUNCH DATE & LATEST EXPIRATION OF CO'S U.S. PATENTS.OMEROS CORP - LUPIN IS GRANTED NON-EXCLUSIVE, NON-SUBLICENSABLE WAIVER OF CO'S PEDIATRIC EXCLUSIVITY FOR OMIDRIA UNTIL AT LEAST APRIL 23, 2034.  Full Article

Omeros Q4 Loss Per Share $0.34
Thursday, 1 Mar 2018 

March 1 (Reuters) - Omeros Corp ::REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.34.Q4 REVENUE $13.8 MILLION.  Full Article

European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros' OMS721
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Omeros Corp ::EUROPEAN MEDICINES AGENCY ISSUES ORPHAN DRUG DESIGNATION POSITIVE OPINION FOR OMEROS’ OMS721 IN THE TREATMENT OF IGA NEPHROPATHY.OMEROS CORP - EMA ALSO REVIEWING PRIORITY MEDICINES APPLICATION FOR DRUG IN IGAN.OMEROS CORP - POSITIVE OPINION ISSUED BY COMP IS EXPECTED TO BE ADOPTED BY EUROPEAN COMMISSION AT ITS FEBRUARY MEETING.  Full Article